Weave Bio

Machine learning to accelerate drug discovery and therapeutic design.

Weave Bio is an AI drug discovery platform that applies machine learning to the design and optimization of novel therapeutics, with the goal of compressing the timeline from target identification to viable drug candidates. Traditional drug discovery is slow and failure-prone; Weave Bio’s platform uses proprietary AI models to navigate the vast chemical and biological search spaces involved in finding molecules with the right combination of efficacy, selectivity, and drug-like properties. The platform targets pharmaceutical and biotech companies — at mid-market and enterprise scale — looking to accelerate early-stage discovery programs or apply AI to specific therapeutic design challenges. It differentiates through proprietary AI models developed for the specific computational biology and chemistry tasks central to drug discovery, rather than applying general-purpose AI to scientific literature.

Compliance

SOC 2

Visit Weave Bio

Key Features

Therapeutic design and optimization: Uses machine learning to generate and evaluate candidate molecules, optimizing for target properties such as binding affinity, selectivity, and pharmacokinetic characteristics.
Target-to-candidate acceleration: Applies AI to compress the time spent between identifying a biological target and producing viable drug candidates ready for experimental validation.
Proprietary biological and chemical AI models: Uses models developed specifically for the molecular biology and medicinal chemistry tasks of drug discovery, rather than adapting general-purpose language models.
Iterative design workflows: Supports iterative cycles of design, prediction, and experimental feedback, allowing research teams to incorporate wet lab results back into the AI-driven design process.
Multi-modality support: Capable of working across relevant modalities in drug discovery — small molecules, biologics, and other therapeutic formats — depending on the program’s requirements.

Use Cases

For pharmaceutical companies accelerating early-stage discovery programs: A pharma company with a validated biological target uses Weave Bio to generate and prioritize candidate molecules, reducing the time and cost of the lead identification and optimization phases.
For biotech companies applying AI to specialized therapeutic areas: A biotech focused on a specific disease area or modality uses Weave Bio’s platform to bring AI-driven design capability to their discovery pipeline without building an internal computational biology team from scratch.

Pricing MODELS

Enterprise

Pricing Summary

Weave Bio uses a custom enterprise pricing model. No self-serve tiers or publicly listed prices are available — organizations engage with the company directly for pricing.